Reuters logo
BRIEF-Glaxosmithkline Says ‍New Data From Phase III Clinical Study Supports Safety And Efficacy
December 6, 2017 / 7:18 AM / 10 days ago

BRIEF-Glaxosmithkline Says ‍New Data From Phase III Clinical Study Supports Safety And Efficacy

Dec 6 (Reuters) - Glaxosmithkline Plc:

* ‍NEW DATA FROM A PHASE III CLINICAL STUDY SUPPORTS SAFETY AND EFFICACY OF SHINGRIX IN PREVENTING SHINGLES​

* ZOE-HSCT STUDY SUCCEEDED PRIMARY OBJECTIVE BY DEMONSTRATING AN EFFICACY OF 68.17% AGAINST SHINGLES IN SUBJECTS ABOVE 18 YEARS OF AGE​ Source text for Eikon: Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below